2026 AHA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM): An Evolution in Management
Jersey Desk/10343937

HAZLET, N.J. - JerseyDesk -- In this symposium, ATTR experts will describe strategies for improving recognition of clinical clues for ATTR-CM and for making an earlier and accurate diagnosis. Evidence with disease-modifying therapies for ATTRCM will be presented including interpretations of recently completed clinical trials. Most effective use of HF medications in ATTR-CM patients will also be discussed. Two cases with panel discussions will be presented, 1) avoiding pitfalls and explaining best practices to overcome management challenges, and 2) successfully addressing the complexities of diagnosing hereditary ATTR-CM and recognizing the importance of genetic testing not only for the index patient but also for identifying at-risk family members and initiating evidence-based interventions.

Click here for more information

More on Jersey Desk

• YMCA Alliance Launches Expanded Bright Path Youth Mental Health Program
• Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
• Electronic Office Systems Named ENX Magazine Elite Dealer for 26th Consecutive Year
• Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
• ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains

CHAIR

Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Sarah Cuddy, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Justin Grodin, MD, MPH
Associate Professor of Medicine
Department of Internal Medicine – Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, Texas

Ahmad Masri, MD, MS
Associate Professor of Medicine
Oregon Health & Science University
Portland, Oregon

Educational Objectives

• Identify suggestive findings for ATTR-CM
• Summarize the diagnostic evaluation for cardiac amyloidosis
• Interpret the evidence for ATTR-CM disease-modifying therapies
• Discuss strategies for the use of HF medications in patients diagnosed with ATTR-CM
• Explain the importance of genetic testing in the diagnosis of ATTR-CM
• Describe the challenges associated with the management of transthyretin amyloidosis

Target Audience

More on Jersey Desk

• Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
• Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
• The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
• New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
• Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30

This educational activity is intended for cardiovascular clinicians.

Educational Grant

Voxmedia gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP and Ionis Pharmaceuticals.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.